TRiCares Secures $50M For Tricuspid Replacement System, Topaz

 
• By Natasha Barrow

TRiCares SAS announced it raised $50m in series D funding from a single unnamed investor. The funding will support the company’s upcoming US early feasibility study and EU CE mark clinical investigation for its transfemoral tricuspid heart valve replacement system, Topaz.

Topaz transfemoral tricuspid heart valve replacement system
• Source: TRiCares SAS

More from Europe

More from Geography